Compare Globus Medical Inc. Class A Common Stock (GMED) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while YieldMax NVDA Option Income Strategy ETF trades at $11.92 (market cap $1.39B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 7.4× YieldMax NVDA Option Income Strategy ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and YieldMax NVDA Option Income Strategy ETF for 44 Days on average.
| GMED | NVDY | |
|---|---|---|
Market Cap | $10.25B | $1.39B |
Volume | 1,108,124 | 1,855,603 |
Sector | Health | Income / Options Overlay |
52-Week High | $96.82 | $17.21 |
52-Week Low | $58.33 | $11.58 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.54, up 0.88% on the day. The technical outlook is bearish, with moving averages signaling strong selling pressure, though oscillators are neutral. The fund generates weekly dividends but faces structural limitations on upside participation. Recent news highlights concerns over net asset value erosion despite high distribution yields.
The outlook is cautious; while NVDY offers high income, its strategy caps gains during NVIDIA rallies and may underperform in low-volatility environments. Key risks include NAV decay and reduced option income potential. Investors seeking pure NVIDIA exposure may find direct ownership more attractive for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
